All the Active Ingredient Drugs
Selective Norepinephrine Reuptake Inhibitor. Atomoxetine (as HCl) 25, 40, 60 mg. F.C. TABS.: 28×25, 40, 60mg. Paed. pts. up to 70 kg bdy. wt.: Initial. at a total dly dose of approx. 0.5 mg/kg. The initial dose should be maintain. for a min. of 7 d. prior to upward dose titrat. accord. to clinical response and tolerab. The recommended mainten. dose is approx. 1.2 mg/kg/d. (depend. on the pt’s. wt. and available dosage strengths of atomoxetine).
Dosing of paed. pts. over 70 kg bdy. wt. and Adult.: The Drug should be initiated at a total daily dose of 40 mg. The initial dose should be maintain. for a min. of 7 d. prior to upward dose titrat. accord. to clinical response and tolerab.. The recomm. mainten. dose is 80mg. The max. recom. total dly. dose is 100 mg.
Indicated for the tmt. of ADHD in child. of 6 yrs. and older, in adolesc. & in adult. as part of a comprehensive tmt. programme. Tmt. must be initiated by a specialist in the tmt. of ADHD, such as a paediatrician, child/adolesc. psychiatrist, or psychiatrist. Diagnosis should be made accord. to current DSM criteria or the guidelines in ICD. In adult., the presence of sympt. of ADHD that were pre-exist. in childhood should be confirmed. Third-party corroboration is desirable and the drug should not be initiated when the verification of childhood ADHD sympt. is uncertain. Diagnosis cannot be made solely on the presence of one or more sympt. of ADHD. Based on clinical judgment, pts. should have ADHD of at least moder. severity as indicated by at least moderate function. impair. in 2 or more settings (for example, social, academic, and/or occupational functioning), affecting several aspects of an individual’s life.
C/I: Hypersens. Comb. with MAOI. Atomoxetine should not be used within a min. of 14 d. after discont. ther. with MAOI. Tmt. with MAOI should not be init. within 14 d. after discont. atomoxetine.
Pts. with narrow-ang. glauc.
Pts. with pheochromocytom.
Pts. with severe card./vascular disord., hypertens., tachycard.